Compare iShares MSCI South Korea ETF (EWY) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs IDEXX Laboratories, Inc. — how do they compare? iShares MSCI South Korea ETF trades at $176.11, while IDEXX Laboratories, Inc. trades at $571 (market cap $46.22B). The key difference: iShares MSCI South Korea ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| EWY | IDXX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $766.68 |
52-Week Low | $71.22 | $526.44 |
Market Cap | — | $46.22B |
Enterprise Value | — | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY, the iShares MSCI South Korea ETF, trades at $175.87, up 7.82% in 24 hours, with a neutral technical signal overall. Recent news highlights volatility in South Korean equities tied to AI and semiconductor stocks, including government support initiatives and foreign capital outflows. The ETF's technical indicators show mixed signals, with bullish moving averages but neutral oscillators, while support and resistance levels suggest near-term consolidation.
The outlook for EWY hinges on South Korea's semiconductor sector recovery and broader market sentiment. Opportunities include potential rebounds from oversold conditions and government-backed chip investments, but risks involve continued volatility from AI trade unwinds and global macroeconomic pressures. Investor caution is warranted amid mixed analyst views and regulatory scrutiny on leveraged ETFs.
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
